Four autologous anti-CD19 CARTs are approved by the FDA for the treatment of lymphoma, including axicabtagene ciloleucel and tisagenlecleucel for FL and LBCL, lisocabtagene maraleucel for LBCL, and brexucabtagene autoleucel for mantle cell lymphoma [16]. Here, CD19 is linked to lymphoma.